Holen Sie sich die Stockscreener-App
12.15
2.79%
0.33
Handel nachbörslich:
12.15
Schlusskurs vom Vortag:
$11.82
Offen:
$11.63
24-Stunden-Volumen:
749.78K
Relative Volume:
0.73
Marktkapitalisierung:
$380.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-2.1707
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+4.11%
1M Leistung:
-5.67%
6M Leistung:
-70.61%
1J Leistung:
-50.91%
1-Tages-Spanne:
$11.52
$12.50
1-Wochen-Bereich:
$11.21
$12.68
52-Wochen-Spanne:
$11.21
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
12.15 | 369.85M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
Performance Recap: Can LENZ Therapeutics Inc reach all time highs this year2026 Historical Comparison & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday - MarketBeat
William Blair Maintains Outperform on LENZ Therapeutics, Inc (LENZ) March 10 2026 - Meyka
LENZ submits marketing application for presbyopia drug in Europe - Investing.com South Africa
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential By Investing.com - Investing.com Canada
LENZ submits marketing application for presbyopia drug in Europe By Investing.com - Investing.com Australia
LENZ: Rapidly growing prescriber base and strong refill rates highlight successful launch momentum - TradingView
LENZ: Strong launch for a new presbyopia eye drop, with rapid adoption and robust safety profile - TradingView
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential - Investing.com
LENZ Therapeutics Submits Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia - LENZ Therapeutics
New eye drop for age-related blurry vision heads to EU review - Stock Titan
Tyro Capital Management LLC Makes New $4.69 Million Investment in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
Aug Sentiment: Is LENZ Therapeutics Inc a strong candidate for buy and hold2026 Price Momentum & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Market Pulse: Why is LENZ Therapeutics Inc stock going upMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Presbyopia Pipeline 2026: 10+ Companies, 10+ Emerging Therapies, and 3 Key FDA NDA Milestones Driving the Future of Vision Care, analyses DelveInsight - StreetInsider
LENZ: Strong launch momentum for a new presbyopia eye drop, with robust efficacy and market uptake - TradingView
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Should You Buy LENZ Therapeutics Inc (LENZ) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
LENZ Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Bearish Setup: What are LENZ Therapeutics Incs recent SEC filings showingMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
LENZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Versant Venture Management LLC Buys Shares of 2,656,888 LENZ Therapeutics, Inc. $LENZ - MarketBeat
LENZ Therapeutics to Present at Upcoming Investor Conferences - LENZ Therapeutics
Presbyopia eye-drop firm LENZ lines up two investor conferences - Stock Titan
Risk Check: Can LENZ Therapeutics Inc sustain its profitabilityGold Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen - MarketBeat
What’s the beta of LENZ Therapeutics Inc. stockQuarterly Profit Review & Breakout Confirmation Trade Signals - mfd.ru
Breakout Move: What are LENZ Therapeutics Incs recent SEC filings showingWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Weekly Earnings: Can LENZ Therapeutics Inc reach all time highs this yearMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
LENZ Therapeutics, Inc. $LENZ Shares Acquired by Skandinaviska Enskilda Banken AB publ - MarketBeat
Ridgeback exits Lenz Therapeutics (LENZ) with 0% reported ownership stake - Stock Titan
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Decreases By 16.8% - MarketBeat
How LENZ Therapeutics Inc. stock compares to market leaders2025 EndofYear Setup & Fast Gain Stock Trading Tips - mfd.ru
LENZ Therapeutics (LENZ) Stock Analysis: Eyeing A 295% Upside In The Biotech Arena - DirectorsTalk Interviews
Analyst Upgrade: Can LENZ Therapeutics Inc disrupt its industryNew Guidance & Consistent Income Trade Recommendations - baoquankhu1.vn
Why is LENZ Therapeutics Inc. stock going upWeekly Stock Report & Reliable Price Action Trade Plans - mfd.ru
Fund Flows: What is the cash position of LENZ Therapeutics IncEarnings Recap Report & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can LENZ Therapeutics Inc. benefit from deglobalizationJuly 2025 Momentum & Low Risk Growth Stock Ideas - mfd.ru
Is LENZ Therapeutics Inc. stock a value trapBreakout Watch & Advanced Technical Signal Analysis - mfd.ru
Is LENZ Therapeutics Inc. benefiting from interest rate changesWeekly Trading Summary & Low Risk High Win Rate Picks - mfd.ru
Guidance Update: Can LENZ Therapeutics Inc be the next market leaderEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
Investment Recap: Why is LENZ Therapeutics Inc stock going upQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), LENZ Therapeutics (LENZ) and Amgen (AMGN) - The Globe and Mail
Lenz Therapeutics price target lowered to $35 from $52 at BofA - TipRanks
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp - Investing.com Canada
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp By Investing.com - Investing.com South Africa
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):